<code id='254A779A33'></code><style id='254A779A33'></style>
    • <acronym id='254A779A33'></acronym>
      <center id='254A779A33'><center id='254A779A33'><tfoot id='254A779A33'></tfoot></center><abbr id='254A779A33'><dir id='254A779A33'><tfoot id='254A779A33'></tfoot><noframes id='254A779A33'>

    • <optgroup id='254A779A33'><strike id='254A779A33'><sup id='254A779A33'></sup></strike><code id='254A779A33'></code></optgroup>
        1. <b id='254A779A33'><label id='254A779A33'><select id='254A779A33'><dt id='254A779A33'><span id='254A779A33'></span></dt></select></label></b><u id='254A779A33'></u>
          <i id='254A779A33'><strike id='254A779A33'><tt id='254A779A33'><pre id='254A779A33'></pre></tt></strike></i>

          Home / Wikipedia / leisure time

          leisure time


          leisure time

          author:fashion    Page View:12
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In